Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA

Murat Fani Bozkurt, Irene Virgolini, Sona Balogova, Mohsen Beheshti, Domenico Rubello, Clemens Decristoforo, Valentina Ambrosini, Andreas Kjaer, Roberto Delgado-Bolton, Jolanta Kunikowska, Wim J.G. Oyen, Arturo Chiti, Francesco Giammarile, Stefano Fanti

Research output: Contribution to journalArticlepeer-review


Purpose & Methods: Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms. Results & Conclusion: The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.

Original languageEnglish
Pages (from-to)1588-1601
Number of pages14
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number9
Publication statusPublished - Aug 1 2017


  • F–DOPA
  • F–FDG
  • Foregut-NET
  • Hindgut-NET
  • Hyperinsulism in infants
  • Midgut-NET
  • Neuroendocrine neoplasms
  • Neuroendocrine tumours
  • Paraganglioma
  • Pet/Ct
  • Pheochromoacytoma
  • Thyroid medullary cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Guideline for PET/CT imaging of neuroendocrine neoplasms with <sup>68</sup>Ga-DOTA-conjugated somatostatin receptor targeting peptides and <sup>18</sup>F–DOPA'. Together they form a unique fingerprint.

Cite this